TABLE 3.
Prognostic factors affecting OS in the nontransplanted ATLL patient cohort
| Variables | Number a | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | ||
| ECOG PS | |||||
| 0, 1 | 63 | 1.000 | Reference | 1.000 | Reference |
| 2, 3, 4 | 23 | 3.981 (2.004‐7.906) | <.0001 | 4.540 (1.495‐13.791) | .008 |
| Clinical variant | |||||
| Indolent | 8 | 1.000 | Reference | 1.000 | Reference |
| Aggressive | 78 | 2.235 (0.539‐9.273) | .268 | 1.601 (0.371‐6.911) | .528 |
| Age (years) | |||||
| ≤70 | 53 | 1.000 | Reference | 1.000 | Reference |
| >70 | 33 | 1.046 (0.552‐1.979) | .891 | 1.333 (0.668‐2.662) | .415 |
| Serum sIL‐2R (U/mL) | |||||
| ≤20 000 | 53 | 1.000 | Reference | 1.000 | Reference |
| >20 000 | 33 | 2.142 (1.139‐4.031) | .018 | 1.241 (0.606‐2.540) | .555 |
| Serum Alb (g/dL) | |||||
| ≥3.5 | 63 | 1.000 | Reference | 1.000 | Reference |
| <3.5 | 23 | 2.322 (1.184‐4.557) | .014 | 1.402 (0.478‐4.115) | .538 |
| CD28 protein overexpression | |||||
| Absence | 46 | 1.000 | Reference | 1.000 | Reference |
| Presence | 40 | 2.323 (1.184‐4.557) | .014 | 2.137 (1.118‐4.084) | .022 |
Abbreviations: Alb, albumin; ATLL, adult T‐cell leukemia/lymphoma; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PS, performance status; sIL‐2R, soluble interleukin‐2 receptor.
a
Of the 92 patients, six were excluded because of missing data.